dm+d

Unassigned

New Medicines

Imprime PGGColorectal cancer - in combination with atezolizumab and bevacizumab

Information

Imprime PGG
New molecular entity
Biothera
Biothera

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials

Category

Immunostimulant
Colorectal cancer is the third most common cancer in the UK after breast and lung cancer, with approximately 40,000 new cases registered each year. Colorectal cancer is the second most common cause of cancer death in the UK. The age-standardised incidence rate per 100,000 population in the UK in 2008 was 47.2 (29.4 colon, 17.8 rectum). The figures were higher for men than women for both colon and rectal cancers. [2]
Colorectal cancer - in combination with atezolizumab and bevacizumab
Intravenous